Somme, Laura Bender http://orcid.org/0000-0003-3486-8505
Chouaid, Christos
Moinard-Butot, Fabien
Barbe-Richaud, Jean-Baptiste
Greillier, Laurent
Schott, Roland
Article History
Accepted: 22 April 2024
First Online: 20 May 2024
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Laura Bender Somme: MSD, Novartis, Daiichi Sankyo, Takeda. Christos Chouaid: AstraZeneca, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer and Amgen. Roland Schott: Bristol-Myers Squibb/Celgene, Roche, AstraZeneca. Laurent Greillier: BMS, MSD, Takeda, Pfizer, Roche, Novartis, Amgen, Lilly, Jansen. Fabien Moinard-Butot and Jean-Baptiste Barbe-Richaud declare they have no conflicts of interest that might be relevant to the contents of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: LBS, RS and CC performed the material preparation, data collection and analysis. LBS wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript, and read and approved the final manuscript.